Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Daiichi Sankyo to Take Sole Charge of Emgality Information Activities
Daiichi Sankyo will take sole responsibility for providing information to healthcare professionals on migraine drug Emgality (galcanezumab) in Japan from January 1, 2027, ending the current joint arrangement with Eli Lilly Japan. Lilly will remain the marketing authorization holder for…
To read the full story
Related Article
BUSINESS
- Kyowa Finds Nitrosamines in 2 Antidepressants; No Recall Planned
October 6, 2026
- Nippon Zoki Bags Japan Rights to Taiwan Firm’s Knee Osteoarthritis Drug
October 6, 2026
- AstraZeneca, Academic Society Join Hands on Obesity Care in Japan
October 6, 2026
- Daiichi Sankyo to Take Sole Charge of Emgality Information Activities
October 6, 2026
- Shionogi to Buy IntraBio for US$2 Billion, Gains Rare Disease Drug
October 6, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…